25
Views
2
CrossRef citations to date
0
Altmetric
LETTER TO THE EDITOR

Bevacizumab may be Active in Myelofibrosis

, , , , , & show all
Pages 111-112 | Published online: 09 Dec 2009

REFERENCES

  • Lundberg, L.G.; Lerner, R.; Sundelin, P.; Rogers, R.; Folkman, J.; Palmbad, J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000, 157(1), 15–19.
  • Steurer, M.; Zoller, H.; Augustin, F.; Fong, D.; Heiss, S.; Strasser-Weippl, K.; Gastl, G.; Tzankov, A. Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. Hum Pathol 2007, 38(7), 1057–1064.
  • Ni, H.; Barosi, G.; Hoffman, R. Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis. Am J Clin Pathol 2006, 126(2), 241–247.
  • Klener, P. Some new findings in the pathogenesis of myeloproliferative disorders and new insight into more effective treatment Cas Lek Cesk 2006, 145(1), 4–8 (abstract).
  • Aguiar Bujanda, D. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Letter to the editor. Ann Oncol 2008, 19(2), 396–397.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.